Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1391

1.

Nutrition care guidelines for men with prostate cancer undergoing androgen deprivation therapy: do we have enough evidence?

Barnes KA, Ball LE, Galvão DA, Newton RU, Chambers SK.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0099-9. [Epub ahead of print]

PMID:
30279584
2.

Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning.

Simmons LAM, Kanthabalan A, Arya M, Briggs T, Charman SC, Freeman A, Gelister J, Jameson C, McCartan N, Moore CM, van der Muelen J, Emberton M, Ahmed HU.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0094-1. [Epub ahead of print]

PMID:
30279583
3.

Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0095-0. [Epub ahead of print]

PMID:
30279582
4.

Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy.

Tan WP, Papagiannopoulos D, Latchamsetty KC, Wilson N, O'Block N, Raff L, Lora AM, Coogan CL, Abern MR.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0092-3. [Epub ahead of print]

PMID:
30279581
5.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0096-z. [Epub ahead of print]

PMID:
30279580
6.

PTEN status assessment in the Johns Hopkins active surveillance cohort.

Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0093-2. [Epub ahead of print]

PMID:
30279579
7.

Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis.

Dobbs RW, Malhotra NR, Abern MR, Moreira DM.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0097-y. [Epub ahead of print]

PMID:
30279578
8.

Updates in advanced prostate cancer 2018.

Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0100-7. [Epub ahead of print] No abstract available.

PMID:
30279577
9.

Nocturia and associated mortality: observational data from the REDUCE trial.

Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Sep 13. doi: 10.1038/s41391-018-0090-5. [Epub ahead of print]

PMID:
30214036
10.

Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data.

Jeong CW, Kang M, Il Jung S, Kim TH, Park SW, Joung JY, Jeon SS, Hong JH, Lee JY, Chung BH, Ahn H, Kim CS, Kwon DD, Kwak C.

Prostate Cancer Prostatic Dis. 2018 Sep 13. doi: 10.1038/s41391-018-0088-z. [Epub ahead of print]

PMID:
30214035
11.

Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.

Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2018 Sep 13. doi: 10.1038/s41391-018-0087-0. [Epub ahead of print]

PMID:
30214034
12.

Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.

Chattopadhyay S, Hemminki O, Försti A, Sundquist K, Sundquist J, Hemminki K.

Prostate Cancer Prostatic Dis. 2018 Sep 5. doi: 10.1038/s41391-018-0089-y. [Epub ahead of print]

PMID:
30185889
13.

Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.

Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2018 Aug 31. doi: 10.1038/s41391-018-0084-3. [Epub ahead of print]

PMID:
30171230
14.

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.

Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2018 Aug 31. doi: 10.1038/s41391-018-0086-1. [Epub ahead of print]

PMID:
30171229
15.

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.

Möller A, Olsson H, Grönberg H, Eklund M, Aly M, Nordström T.

Prostate Cancer Prostatic Dis. 2018 Aug 31. doi: 10.1038/s41391-018-0082-5. [Epub ahead of print]

PMID:
30171228
16.

Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.

Krimphove MJ, Cole AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, Sun M, Nabi J, Nguyen PL, Hu JC, Kibel AS, Choueiri TK, Kluth LA, Trinh QD.

Prostate Cancer Prostatic Dis. 2018 Aug 31. doi: 10.1038/s41391-018-0083-4. [Epub ahead of print]

PMID:
30171227
17.

Estrogens and prostate cancer.

Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR.

Prostate Cancer Prostatic Dis. 2018 Aug 21. doi: 10.1038/s41391-018-0081-6. [Epub ahead of print]

PMID:
30131606
18.

BRCAness and prostate cancer: diagnostic and therapeutic considerations.

Dhawan M, Ryan CJ.

Prostate Cancer Prostatic Dis. 2018 Aug 21. doi: 10.1038/s41391-018-0069-2. [Epub ahead of print]

PMID:
30131605
19.

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L.

Prostate Cancer Prostatic Dis. 2018 Aug 21. doi: 10.1038/s41391-018-0079-0. [Epub ahead of print]

PMID:
30131604
20.

Bipolar plasma enucleation of the prostate vs. open prostatectomy in large benign prostatic hyperplasia: a single centre 3-year comparison.

Giulianelli R, Gentile BC, Mirabile G, Tema G, Albanesi L, Tariciotti P, Rizzo G, Falavolti C, Aloisi P, Vincenti G, Lombardo R.

Prostate Cancer Prostatic Dis. 2018 Aug 21. doi: 10.1038/s41391-018-0080-7. [Epub ahead of print]

PMID:
30131603

Supplemental Content

Loading ...
Support Center